Diccard hydrogel composition and application thereof
By developing a dual-cluster hydrogel composition containing carbomer, carrageenan, glycerol, isomaltose and recombinant protein, forming a protective gel membrane on the vaginal wall, HPV infection in the prior art is solved by developing a dual-cluster hydrogel composition containing carbomer, carrageenan, glycerol, isomaltose and recombinant protein, a protective gel membrane is formed on the vaginal wall. The lack of simple and non-invasive prevention and treatment methods has enabled effective blocking of HPV infection and reducing the risk of precancerous cervical lesions.
Patent Information
- Application Number
- CN202411146538.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-20
- Publication Date
- 2024-11-26
AI Technical Summary
The prior art methods for preventing and treating cervical cancer are limited, especially in the lack of simple and non-invasive effective measures for HPV infection.
Develop a dual-card hydrogel composition containing carbomer, carrageenan, glycerol, isomaltose oligosaccharide, sodium methyl paraben and specific recombinant proteins by forming a protective gel membrane on the vaginal wall , physically isolate pathogenic microorganisms and block HPV infection by electrostatic adsorption.
Effectively reducing HPV viral load and preventing the occurrence of precancerous cervical lesions, it provides a simple and non-invasive method to prevent and treat HPV infection.
Smart Images

Figure BDA0005002348250000081
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biomedicine and medical devices, and in particular to a dual-card hydrogel composition and application thereof. Background Art
[0002] Papillomaviruses are double-stranded DNA viruses that make up the genus Papillomavirus in the family Papillomaviridae. Papillomaviruses are highly species-specific, and human papillomavirus (HPV) only infects humans. There are more than 200 subtypes of HPV, which can be divided into skin-tropic and mucotropic types based on the tissue tropism of HPV.
[0003] Most HPV infections usually resolve within 12 months. However, if an oncogenic HPV infection persists for more than 12 months, the likelihood of developing precancerous or cancerous lesions increases, but not all persistent infections progress.
[0004] Different HPV subtypes have a tendency to infect different parts of the body and can therefore cause different diseases.
[0005] Certain HPV subtypes prefer to infect the skin epithelium and are found in plantar warts, common warts, flat warts, and butcher's warts. Some HPV subtypes prefer to infect the keratinized skin and mucosa of the anogenital area. Common sites of infection include: penis, scrotum, perineum, anal canal, perianal area, vaginal opening, vulva, and cervix. More than 40 types of mucosal HPV can infect the genital tract. The manifestations of anogenital diseases are also different when infected with different subtypes of HPV. Genital warts (condyloma acuminatum) are most commonly caused by HPV types 6 and 11. About 15 HPV subtypes are associated with squamous intraepithelial neoplasia of the vagina, vulva, cervix, anus, or penis and are referred to as high-risk, carcinogenic, or cancer-associated.
[0006] In addition, HPV types 6 and 11 can infect the respiratory mucosa, especially in infants and young children.
[0007] Cervical cancer is the fourth most common female cancer in the world, with approximately 600,000 cases of invasive cervical cancer diagnosed and 300,000 deaths each year. HPV is a key factor in the formation of cervical tumors and can be detected in 99.7% of cervical cancers. Almost all cases of cervical cancer are caused by HPV infection. The most common histological types of cervical cancer are squamous cell carcinoma (70%) and adenocarcinoma (25%). Currently, there are limited clinical treatment options, and there is an urgent need to develop new, simple and non-invasive prevention and treatment methods. Summary of the invention
[0008] In a first aspect of the present invention, a protein is provided, wherein the amino acid sequence of the protein is as shown in SEQ ID NO: 1 or 3.
[0009] In some embodiments of the present invention, the amino acid sequence of the protein is shown in SEQ ID NO:1.
[0010] In some embodiments of the present invention, the amino acid sequence of the protein is shown in SEQ ID NO:3.
[0011] In the second aspect of the present invention, a nucleic acid is provided, characterized in that the nucleic acid encodes the protein described in the present invention.
[0012] In some embodiments of the present invention, the nucleic acid encodes a protein having an amino acid sequence as shown in SEQ ID NO: 1 or 3.
[0013] In some embodiments of the present invention, the nucleic acid encodes a protein having an amino acid sequence as shown in SEQ ID NO:1.
[0014] In some embodiments of the invention, the nucleic acid encodes a protein having an amino acid sequence as shown in SEQ ID NO:3.
[0015] In the third aspect of the present invention, a vector is provided, characterized in that the vector comprises a nucleotide sequence encoding a protein having an amino acid sequence as shown in SEQ ID NO: 1 or 3.
[0016] In some embodiments of the present invention, the vector comprises a nucleotide sequence encoding a protein having an amino acid sequence as shown in SEQ ID NO:1.
[0017] In some embodiments of the present invention, the vector comprises a nucleotide sequence encoding a protein having an amino acid sequence as shown in SEQ ID NO:3.
[0018] In some embodiments of the present invention, the vector further comprises a regulatory control element, and the regulatory control element can regulate the expression of the protein.
[0019] For example, for prokaryotic cells, these regulatory control elements include promoters, terminators, signals that regulate gene expression (e.g., repressors, stimulators, etc.), signals associated with translation, signals associated with nucleic acid modification (e.g., by methylation modification), etc. For eukaryotic cells, other regulatory control elements include signals associated with splicing, post-translational modification, etc.
[0020] In a fourth aspect of the present invention, a cell is provided, characterized in that the cell comprises the protein, nucleic acid, and / or vector of the present invention.
[0021] In some embodiments of the invention, the cell is a eukaryotic cell. In some embodiments of the invention, the cell is a prokaryotic cell.
[0022] In a fifth aspect of the present invention, a method for preparing a recombinant protein is provided, wherein the preparation method is as described in Example 1.
[0023] In a sixth aspect of the present invention, there is provided use of the protein of the present invention in the preparation of medical devices and / or drugs for treating HPV virus infection.
[0024] In some embodiments of the present invention, there is provided a use of the protein of the present invention in the preparation of a drug for treating HPV virus infection. In some embodiments of the present invention, there is provided a use of the protein of the present invention in the preparation of a medical device for HPV virus infection.
[0025] In some embodiments of the present invention, the amino acid sequence of the protein is shown in SEQ ID NO: 1 or 3. In some embodiments of the present invention, the amino acid sequence of the protein is shown in SEQ ID NO: 1.
[0026] In some embodiments of the present invention, the HPV is any one of HPV subtypes 1-89.
[0027] In some embodiments of the present invention, the HPV virus is HPV18 virus or HPV6 virus. In some embodiments of the present invention, the HPV virus is HPV18 virus. In some embodiments of the present invention, the HPV virus is HPV6 virus.
[0028] In a seventh aspect of the present invention, a composition is provided, characterized in that the composition comprises:
[0029] 0.2%-0.4% by weight of carbomer, 0.6%-1.0% by weight of sodium alginate, 0.3%-0.5% by weight of carrageenan, 6%-10% by weight of glycerol, 3%-5% by weight of isomaltooligosaccharide, 0.1%-0.2% by weight of sodium methyl paraben and 0.6%-1.0% by weight of the protein as described in the first aspect of the present invention.
[0030] In some embodiments of the invention, the composition is a gel.
[0031] In some embodiments of the present invention, a composition is provided, characterized in that the composition comprises:
[0032] 0.2%-0.4% by weight of carbomer, 0.6%-1.0% by weight of sodium alginate, 0.3%-0.5% by weight of carrageenan, 6%-10% by weight of glycerol, 3%-5% by weight of isomaltooligosaccharide, 0.1%-0.2% by weight of sodium methyl paraben and 0.6%-1.0% by weight of recombinant protein; the amino acid sequence of the recombinant protein is shown in SEQ ID NO:1.
[0033] In some embodiments of the present invention, a composition is provided, characterized in that the composition comprises:
[0034] 0.2%-0.4% by weight of carbomer, 0.6%-1.0% by weight of sodium alginate, 0.3%-0.5% by weight of carrageenan, 6%-10% by weight of glycerol, 3%-5% by weight of isomaltooligosaccharide, 0.1%-0.2% by weight of sodium methyl paraben, 0.6%-1.0% by weight of recombinant protein, and the balance of water; the amino acid sequence of the recombinant protein is shown in SEQ ID NO: 1.
[0035] The present invention provides a composition, characterized in that the composition comprises:
[0036] 0.2%-0.4% by weight of carbomer, 0.6%-1.0% by weight of sodium alginate, 0.3%-0.5% by weight of carrageenan, 6%-10% by weight of glycerin, 3%-5% by weight of isomaltooligosaccharide and 0.1%-0.2% by weight of sodium methyl paraben.
[0037] Carbomer can cover the damaged and eroded tissue of the cavity, form a protective film on the mucosal surface, and act as a physical barrier. Carrageenan is a hydrophilic colloid that can play a thickening role, has good stability and film-forming properties, and its natural sulfated polysaccharide structure can physically wrap the virus and play a physical blocking role. Oligomeric isomaltose is a humectant that synergizes with glycerol. Sodium methyl paraben is a preservative with excellent preservative properties. The anti-human papillomavirus (HPV) gel of the present invention forms a protective gel film on the vaginal wall through the gel, which physically isolates the vaginal wall from external bacteria and prevents the colonization of pathogenic microorganisms. Combined with the electrostatic adsorption of the protein described in the first aspect of the present invention and the physical effect, the purpose of blocking HPV infection, reducing HPV viral load, and preventing cervical precancerous lesions is achieved.
[0038] In some embodiments of the present invention, a dual carbomer hydrogel composition is provided, the composition comprising carbomer and carrageenan.
[0039] In some embodiments of the present invention, a dual-carbohydrate hydrogel composition is provided, comprising carbomer, sodium alginate, carrageenan, glycerin, isomaltooligosaccharide and sodium methylparaben.
[0040] In some embodiments of the present invention, a dual carbomer hydrogel composition is provided, the composition comprising carbomer and carrageenan, and the protein as described in the first aspect of the present invention.
[0041] In some embodiments of the present invention, a dual-card hydrogel composition is provided, which comprises 0.2%-0.4% by weight of carbomer, 0.6%-1.0% by weight of sodium alginate, 0.3%-0.5% by weight of carrageenan, 6%-10% by weight of glycerol, 3%-5% by weight of isomaltooligosaccharide and 0.1%-0.2% by weight of sodium methyl paraben.
[0042] In some embodiments of the present invention, the composition further comprises the protein as described in the first aspect of the present invention.
[0043] In some embodiments of the present invention, a dual-card hydrogel composition is provided, which comprises 0.2%-0.4% by weight of carbomer, 0.6%-1.0% by weight of sodium alginate, 0.3%-0.5% by weight of carrageenan, 6%-10% by weight of glycerol, 3%-5% by weight of oligomalto-oligosaccharides, 0.1%-0.2% by weight of sodium methyl paraben and 0.6%-1.0% by weight of the protein as described in the first aspect of the present invention.
[0044] In some embodiments of the invention, the composition comprises a balance of water.
[0045] In some embodiments of the present invention, the composition comprises 0.3% by weight of carbomer, 0.8% by weight of sodium alginate, 0.4% by weight of carrageenan, 8% by weight of glycerol and 4% by weight of isomaltooligosaccharide, 0.15% by weight of sodium methyl paraben and 0.8% by weight of the protein as described in the first aspect of the present invention.
[0046] In some embodiments of the present invention, the carbomer is carbomer 940. In some embodiments of the present invention, the carbomer is carbomer 940 (Aladdin, product number C299587). In some embodiments of the present invention, the composition is as described in the examples of the present invention.
[0047] In some embodiments of the present invention, the composition comprises 0.3% by weight of carbomer, 0.8% by weight of sodium alginate, 0.4% by weight of carrageenan, 8% by weight of glycerol, 4% by weight of isomaltooligosaccharide, 0.15% by weight of sodium methyl paraben and 0.8% by weight of recombinant protein, and the remainder is water; the amino acid sequence of the recombinant protein is shown in SEQ ID NO: 1.
[0048] In some embodiments of the present invention, the composition is prepared by the method described in Example 3.
[0049] In some embodiments of the present invention, the composition is prepared by the following method:
[0050] Heat 60%-80% by weight of purified water to 55° C., add 0.2%-0.4% by weight of Carbomer 940, and stir; add 0.5%-1.0% by weight of sodium alginate and 0.2%-0.6% by weight of carrageenan; stir, and simultaneously add 6%-10% by weight of glycerol and 2%-6% by weight of isomaltooligosaccharide; stir evenly; add 0.1%-0.2% by weight of sodium methyl paraben and 0.6%-1.0% by weight of a protein having an amino acid sequence as shown in SEQ ID NO:1; stir evenly; add purified water to a total amount of 100% by weight; adjust the pH value to 4.0-5.0 using 1-3 mol / L hydrochloric acid; and cool to obtain the product.
[0051] In some embodiments of the present invention, the composition is prepared by the following method:
[0052] Heat 70 g of purified water to 55° C., add 0.3 g of Carbomer 940, and stir for 2 hours; add 0.8 g of sodium alginate and 0.4 g of carrageenan; continue stirring for 0.5 hour, while stirring, add 8 g of glycerol and 4 g of isomaltooligosaccharide; stir for 0.5 hour and mix evenly; add 0.15 g of sodium methyl paraben and 0.8 g of a protein with an amino acid sequence as shown in SEQ ID NO: 1; stir for 0.5 hour and mix evenly; add purified water to a total of 100 g; adjust the pH value to 4.5 with 2 mol / L hydrochloric acid; and cool naturally to room temperature while stirring to obtain the product.
[0053] In an eighth aspect of the present invention, there is provided use of the composition of the present invention in the preparation of a drug or medical device for treating HPV virus infection.
[0054] In some embodiments of the present invention, there is provided a use of the composition of the present invention in the preparation of a medicament or medical device for HPV virus infection. In some embodiments of the present invention, there is provided a use of the composition of the present invention in the preparation of a medicament for HPV virus infection. In some embodiments of the present invention, there is provided a use of the composition of the present invention in the preparation of a medical device for HPV virus infection.
[0055] In some embodiments of the present invention, there is provided a use of the composition of the present invention in the preparation of a medicament for treating HPV virus infection. In some embodiments of the present invention, there is provided a use of the composition of the present invention in the preparation of a medical device for HPV virus infection.
[0056] In some embodiments of the present invention, the HPV is any one of HPV subtypes 1-89.
[0057] In some embodiments of the present invention, the HPV virus is HPV18 virus or HPV6 virus. In some embodiments of the present invention, the HPV virus is HPV18 virus. In some embodiments of the present invention, the HPV virus is HPV6 virus.
[0058] In a ninth aspect of the present invention, an anti-HPV gel is provided, characterized in that the anti-HPV gel is prepared by the following method:
[0059] Take the composition as described in the seventh aspect of the present invention and fill it into a push syringe in a clean environment to obtain; or
[0060] The protein described in the first aspect of the present invention is taken, filtered through a filter membrane, and then configured to obtain the composition described in the seventh aspect of the present invention, which is then filled into a syringe in a clean environment to obtain the composition.
[0061] In some embodiments of the present invention, the anti-HPV gel is an anti-HPV gel for bolus injection.
[0062] In some embodiments of the present invention, the anti-HPV gel is an anti-HPV gel for skin or mucosal injection.
[0063] In some embodiments of the present invention, the anti-HPV gel is an anti-HPV gel for skin push injection. In some embodiments of the present invention, the anti-HPV gel is an anti-HPV gel for mucosal push injection.
[0064] In some embodiments of the present invention, the mucosa is systemic mucosa. In some embodiments of the present invention, the mucosa is rectal mucosa. In some embodiments of the present invention, the mucosa is anal mucosa. In some embodiments of the present invention, the mucosa is ocular mucosa. In some embodiments of the present invention, the mucosa is canthal mucosa. In some embodiments of the present invention, the mucosa is cervical mucosa. In some embodiments of the present invention, the mucosa is vaginal mucosa. In some embodiments of the present invention, the mucosa is oral mucosa.
[0065] In some embodiments of the present invention, the skin is the skin of the whole body. In some embodiments of the present invention, the skin is the skin of the back of the hand. In some embodiments of the present invention, the skin is the skin of the neck. In some embodiments of the present invention, the skin is the skin of the armpit. In some embodiments of the present invention, the skin is the skin of the pubic region. In some embodiments of the present invention, the skin is the skin on the surface of the penis.
[0066] In some embodiments of the present invention, the filter membrane is a nitrocellulose membrane.
[0067] In some embodiments of the present invention, the filter membrane has a pore size of 0.45 microns.
[0068] In some embodiments of the present invention, the anti-HPV gel is prepared by the following method:
[0069] Take 1.6 g, 2.0 g, 2.5 g, 3.0 g, 3.5 g or 4.0 g of the composition according to the seventh aspect of the present invention, and put it into a push syringe to obtain the composition.
[0070] In the tenth aspect of the present invention, there is provided use of the anti-HPV gel according to the present invention in the preparation of a medical device or a drug for treating HPV virus infection.
[0071] In some embodiments of the present invention, there is provided use of the anti-HPV gel according to the present invention in the preparation of a medical device or a drug for HPV virus infection.
[0072] In some embodiments of the present invention, there is provided a use of the anti-HPV gel of the present invention in the preparation of a medicament for treating HPV virus infection. In some embodiments of the present invention, there is provided a use of the anti-HPV gel of the present invention in the preparation of a medical device for HPV virus infection.
[0073] The protein, composition and gel of the present invention can achieve the effect of inhibiting HPV virus, and thus can be used to prepare anti-HPV drugs and medical devices for HPV virus infection. DETAILED DESCRIPTION
[0074] The present disclosure is further illustrated by way of examples below, but the present disclosure is not limited to the scope of the examples. The experimental methods in the following examples without specifying specific conditions are selected according to conventional methods and conditions, or according to the product instructions. Unless otherwise specified, the reagents and raw materials used in the present disclosure are all commercially available.
[0075] Example 1. Preparation of recombinant collagen
[0076] The nucleic acid fragment encoding the recombinant collagen-like protein (amino acid sequence as shown in SEQ ID NO: 1, named fusion factor PHPV1.5, research and development code FLM1.5) was prepared by outsourcing, and the fragment was cloned into the BlpI and XbaI restriction sites of the pET28a (+) vector. The reaction solution was transformed into stbl3 competent cells and cultured for 16 hours. After that, positive clones were selected, sequenced and identified. Then, the positive clones with correct sequencing were cultured and the expression vector plasmid of the recombinant collagen-like protein (nucleotide sequence as shown in SEQ ID NO: 2) was extracted.
[0077] The obtained recombinant collagen-like protein expression vector plasmid was transformed into BL21 (DE3) competent cells (NEB, C2527I). In LB culture medium containing kanamycin, culture at 37°C for 16 hours. Add IPTG to a concentration of 0.6mM and induce at 16°C for 25 hours. Centrifuge, collect the bacteria, add lysis solution, ultrasonically break them, and centrifuge again to obtain the supernatant containing recombinant collagen-like protein. After filtering with a 0.45μm filter membrane, use Ni-NTA affinity chromatography to purify, and then use ion chromatography. Collect the eluate, freeze-dry, and obtain a recombinant collagen-like protein (SEQ ID NO: 1) with an HPLC purity of 95.6%. This protein sample only presents a single band in SDS-PAGE.
[0078] The same method was used to prepare a control protein (amino acid sequence shown in SEQ ID NO: 3) with an HPLC purity of 96.1%.
[0079] Recombinant collagen (amino acid sequence as shown in SEQ ID NO: 1):
[0080] MKETWWETWWTEWSQPKKKRKV GGGGS GAPGAKGARGSAGPPGATGFPGAKGRV
[0081] GPPPGSGNKGPPGPPGPAGKEGGKGPRGETGPAGRPGEVGPPGPPGPAGEAGSPGADGP
[0082] AGAPGTPGPQGIAGQRGVVGLPGPRGERGFPGLPGPSGEPGKPGPSGASGERGPPGPM
[0083] GPPGLAGPPGESGRMGAPGAEGSPGRDGSPGAKGDRGMTGPAGPPGAPGAPGAPGPV
[0084] GPAGASGDRGETGPAGPAGQVGPVGARGPAGPQGQRGDKGETGEQGDRGIKGHRGFS
[0085] GLQGPPGPPGSPGEQGPSGASGPAGPRGPPGSAGAPGKDGLN GGGGS GRRRRSVQWCAVSQPDAQKCFTWQKNMRKVRGPPVNCIRKESPIQCIQAHHHHHH(SEQ ID NO:1).
[0086] Control protein (amino acid sequence as shown in SEQ ID NO:3):
[0087] MKETWWETWWTEWSQPKKKRKVGGGGSGAPGAKGARGSAGPPGATGFPGAAGRV
[0088] GPPGPSGNAGPPGPPGPAGKEGGKGPRGETGPAGRPGEVGPPGPPGPAGEKGSPGADGP
[0089] AGAPGTPGPQGIAGQRGVVGLPGQRGERGFPGLPGPSGEPGKQGPSGASGERGPPGPM
[0090] GPPGLAGPPGESGREGAPGAEGSPGRDGSPGAKGDRGETGPAGPPGAPGAPGAPGPVG
[0091] PAGKSGDRGETGPAGPAGPVGPVGARGPAGPQGPRGDKGETGEQGDRGIKGHRGFSG
[0092] LQGPPGPPGSPGEQGPSGASGPAGPRGPPGSAGAPGKDGLNGGGGSGRRRRSVQWCAVSQPEATKCFQWQRNMRKVRGPPVSCIKRDSPIQCIQAHHHHHH(SEQ ID NO:3).
[0093] Human α-defensin 5 (SEQ ID NO: 4):
[0094] ATCYCRTGRCATRESLSGVCEISGRLYRLCCR.
[0095] Example 2: Antiviral activity detection
[0096] The antiviral activity of the recombinant collagen prepared by the method described in Example 1 was determined according to a method substantially the same as that in the literature Int J Mol Sci. 2019 Nov 1; 20(21): 5455. The specific steps are as follows.
[0097] A retrovirus was prepared, which contained an expression cassette that used HPV-18URR to drive the expression of HPV-18E6 and HPV-18E7. The virus was transduced into HaCaT cells (Yuanjing Bio, YC-A018). The cells were cultured and exposed to aqueous solutions of recombinant collagen-like protein (SEQ ID NO: 1), control protein (SEQ ID NO: 3) or human α-defensin 5 (SEQ ID NO: 4, MCE Cat. No. HY-P5407) at different concentrations (2 μg / mL, 20 μg / mL) from day 6 to day 12; a control group was set up and treated with DMSO. On day 13, the RT-qPCR method was used to detect the percentage of HPV-18 DNA copies per cell in the culture compared to the DMSO control group. The test was repeated 5 times.
[0098] The experimental results are shown in Table 1, and the results are expressed as mean ± standard deviation. The recombinant collagen protein and the control protein have strong activity in inhibiting HPV virus DNA, and are superior to human α-defensin 5, with statistically significant differences (P<0.001). The activity of recombinant collagen protein in inhibiting HPV virus DNA is also superior to that of the control protein (P<0.01). Unexpected technical effects have been achieved.
[0099] Table 1. Antiviral activity test results
[0100]
[0101] Example 3: Preparation of anti-HPV gel
[0102] Heat 70 grams of purified water to 55°C, add 0.3 grams of Carbomer 940 (Aladdin, item number C299587), stir for 2 hours, completely dissolve and form a uniform colloid. Add 0.8 grams of sodium alginate (Shandong Pingju Biotechnology) and 0.4 grams of carrageenan (Aladdin, item number C107615). Continue stirring for 0.5 hours, and all raw materials are completely dissolved. While stirring, add 8 grams of glycerol and 4 grams of oligosaccharides (Wuhan Kemik Biomedicine). Stir for 0.5 hours and mix evenly. Add 0.15 grams of sodium methyl paraben and 0.8 grams of recombinant collagen (SEQ ID NO: 1) prepared by the method described in Example 1. Stir for 0.5 hours and mix evenly. Add purified water to a total of 100 grams. Use 2 mol / L hydrochloric acid to adjust the pH to 4.5. Cool the mixture naturally to room temperature under stirring. Gel 1 is obtained.
[0103] In the same manner, gel 2 was prepared by using a control protein (SEQ ID NO: 3) instead of the recombinant collagen (SEQ ID NO: 1).
[0104] In the same manner, gel 3 was prepared by using an equal amount of purified water instead of recombinant collagen (SEQ ID NO: 1).
[0105] Example 4: In vivo testing in animal models
[0106] SPF female BALB / c mice, body weight 16.1-18.0g. Randomly divided into blank control group, model group, experimental group, 10 mice in each group. Each animal was subcutaneously injected with 0.1 micrograms of estradiol benzoate every morning for 3 consecutive days. On the afternoon of the third day, 25 microliters of HPV pseudovirus HPV6 (Beijing Sanyao Technology, product number 80020) was mixed with 15 microliters of 4% sodium carboxymethyl cellulose and injected into the vagina of mice in the experimental group and model group for infection; 40 microliters of 4% sodium carboxymethyl cellulose were injected into the vagina of mice in the blank control group. After 48 hours, monitoring showed that the model was successfully established.
[0107] Starting from the 4th day, the mice in the experimental group were injected with 100 mg of the gel prepared as described in Example 3 through a vaginal drug delivery device once a day for 20 consecutive days. The blank control group and the model group were replaced with an equal volume of purified water.
[0108] After the last administration, the animals in each group were killed by cervical dislocation, and cervical tissue was obtained by dissection. The tissues and cells were lysed, and the concentration of the target protein HPV6 E7 was determined by the BCA method. The separation gel and the concentrated gel were prepared, loaded, and electrophoresed. The protein on the gel after electrophoresis was transferred to a polyvinylidene fluoride membrane and exposed by ECL color development. The relative expression of the target protein HPV6 E7 was the ratio of the gray value of the target protein HPV6 E7 band to the gray value of the β-actin band. The results are shown in Table 2, and the average value was taken for each group. Compared with the blank control group, the expression level of HPV6 E7 in the model group was significantly increased (P<0.001). The expression levels of HPV6 E7 in experimental groups 1, 2, and 3 were lower than those in the model group, with statistically significant differences (P<0.01). The expression level of HPV6 E7 in experimental group 1 was lower than that in experimental groups 2 and 3, with statistically significant differences (P<0.01). It shows that the gel used can fight HPV infection, and the effect of gel 1 is better than that of gel 2 and gel 3.
[0109] Table 2. Animal model in vivo testing
[0110] Grouping Relative expression of HPV6E7 protein Blank control group 0.01 Model Group 0.40 Experimental group 1 (administered with gel 1) 0.02 Experimental group 2 (administered with gel 2) 0.11 Experimental group 3 (administered gel 3) 0.19
[0111] Example 5. Preparation of anti-HPV gel dressing
[0112] The non-woven fabric of the base material is thoroughly cleaned and sterilized, and cut into a size of 10 cm×8 cm. 15 g of the gel 1 prepared by the method described in Example 3 is evenly coated on the base material. The base material coated with the gel is dried and cured at 35° C. for 5 hours.
[0113] Example 6. Preparation of anti-HPV gel for skin or mucosal injection
[0114] 1.6 g, 2.0 g, 2.5 g, 3.0 g, 3.5 g and 4.0 g of the gel 1 prepared as described in Example 3 were respectively taken and loaded into a push injector to obtain an anti-HPV gel for skin or mucosal push injection.
[0115] A 20 mg / ml aqueous solution of recombinant collagen (SEQ ID NO: 1) was filtered through a 0.45 μm nitrocellulose membrane, and then gel 1 was prepared according to the method described in Example 3 (the difference was that 30 g of purified water was heated to 55° C. and added to the raw materials to mix). 1.6 g of the gel was taken and sealed in a syringe under a clean environment.
[0116] Although the embodiments of the present disclosure have been described above, it is understood that the above embodiments are exemplary and do not constitute limitations to the present disclosure. A person skilled in the art may make changes, modifications and variations to the above embodiments within the scope of the present disclosure.
Claims
1. A protein, characterized in that The amino acid sequence of the protein is shown in SEQ ID NO: 1 or 3.
2. A nucleic acid, characterized in that The nucleic acid encodes the protein according to claim 1.
3. A carrier, characterized in that The vector comprises a nucleotide sequence encoding a protein having an amino acid sequence as shown in SEQ ID NO: 1 or 3.
4. Use of the protein according to claim 1 in the preparation of drugs or medical devices for HPV virus infection; Optionally, the HPV is any one of HPV subtypes 1-89.
5. A composition, characterized in that The composition comprises: 0.2%-0.4% by weight of carbomer, 0.6%-1.0% by weight of sodium alginate, 0.3%-0.5% by weight of carrageenan, 6%-10% by weight of glycerol, 3%-5% by weight of isomaltooligosaccharide, 0.1%-0.2% by weight of sodium methyl paraben, 0.6%-1.0% by weight of recombinant protein, and the balance of water; the amino acid sequence of the recombinant protein is shown in SEQ ID NO:
1.
6. A composition, characterized in that The composition comprises: 0.3% by weight of carbomer, 0.8% by weight of sodium alginate, 0.4% by weight of carrageenan, 8% by weight of glycerol, 4% by weight of isomaltooligosaccharide, 0.15% by weight of sodium methyl paraben and 0.8% by weight of recombinant protein, and the balance of water; the amino acid sequence of the recombinant protein is shown in SEQ ID NO:
1.
7. A composition, characterized in that The composition is prepared by the following method: Heat 60%-80% by weight of purified water to 55° C., add 0.2%-0.4% by weight of Carbomer 940, and stir; add 0.5%-1.0% by weight of sodium alginate and 0.2%-0.6% by weight of carrageenan; stir, and simultaneously add 6%-10% by weight of glycerol and 2%-6% by weight of isomaltooligosaccharide; stir evenly; add 0.1%-0.2% by weight of sodium methyl paraben and 0.6%-1.0% by weight of a protein having an amino acid sequence as shown in SEQ ID NO:1; stir evenly; add purified water to a total amount of 100% by weight; adjust the pH value to 4.0-5.0 using 1-3 mol / L hydrochloric acid; and cool to obtain the product.
8. A composition, characterized in that The composition is prepared by the following method: Heat 70 g of purified water to 55° C., add 0.3 g of Carbomer 940, and stir for 2 hours; add 0.8 g of sodium alginate and 0.4 g of carrageenan; continue stirring for 0.5 hour, while stirring, add 8 g of glycerol and 4 g of isomaltooligosaccharide; stir for 0.5 hour and mix evenly; add 0.15 g of sodium methyl paraben and 0.8 g of a protein with an amino acid sequence as shown in SEQ ID NO: 1; stir for 0.5 hour and mix evenly; add purified water to a total of 100 g; adjust the pH value to 4.5 with 2 mol / L hydrochloric acid; and cool naturally to room temperature while stirring to obtain the product.
9. An anti-HPV gel, characterized in that: The anti-HPV gel is prepared by the following method: Take the composition as described in any one of claims 5 to 8, and fill it into a syringe in a clean environment to obtain the product.
10. Use of the composition according to any one of claims 5 to 8 or the anti-HPV gel according to claim 9 in the preparation of a medicine or medical device for HPV virus infection; Optionally, the HPV is any one of HPV subtypes 1-89.
